Eyeing Up the New World Order of Injectables in nAMD and DME Management

Outcomes from pinnacle clinical studies and real-world studies evaluating the management of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies are often not comparable. These discrepancies, in part, have been associated with treatment burden and a lack of patient adherence. The refinement of treatment protocols with FDA-approved therapies that extend the interval between dosing schedules help to address these discrepancies. Furthermore, the integration into practice of novel agents with unique mechanisms of action further address the burden of treatment, while providing visual acuity gains. In this continuing medical education activity, experts in the field examine new strategies that increase the treatment intervals of currently available injectable therapies and assess new clinical evidence regarding efficacy and safety of new injectable treatment regimens in patients with nAMD and DME.